Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

By Eric Van Cutsem, H. Lenz, C. Köhne, V. Heinemann, S. Tejpar, I. Melezínek, F. Beier, C. Stroh, P. Rougier, J. Han van Krieken and 1 more. Journal of Clinical Oncology, 2015

760 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/be3d72b92095b6c62d4d4337c355bbe289d5c146

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Rossman
2. G. A. Hobbs
3. Fortunato Ciardiello
4. C. Der

In Pulmonary and Respiratory Medicine

1. C. Der

Citations in the corpus

• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, background): “Independent from tumour localization, RAS mutant tumour status is known to be a very strong negative predictor for EGFR antibody therapy whilst, RAS wt tumour status is a relatively strong predictive marker for the efficacy of EGFR antibody therapy [43, 45, 46, 58].”
• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017, methodology): “Study Design and Patients The CRYSTAL and FIRE-3 study designs, treatment parameters, andeligibilitycriteriahavebeenpreviously reported.(1-4)”
• The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges (2019, background): “The National Comprehensive Cancer Network (NCCN) guidelines for colorectal cancer recommend that patients should screen for KRAS/ NRAS/BRAF mutations, because these mutations are indicative of poor response to cetuximab and panitumumab [159-162].”
• RAS isoforms and mutations in cancer at a glance (2016, background): “This issue continues to evolve (Van Cutsem et al., 2015) because the National Comprehensive Cancer Network recommendation now indicates that CRC patients with any KRAS orNRASmutation, including those of Q61 and A146, will not benefit from anti-EGFR therapy (Tran et al., 2015).”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, methodology): “was observed in the CRYSTAL study evaluating FOLFIRI+/- cetuxumab in the same clinical setting [63-65].”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Furthermore, recent evidence from the PRIME study with panitumumab [48], from the CRYSTAL study with cetuximab [49] and from other studies of EGFR monoclonal antibody therapies has shown that mutations other than those in KRAS exon 2 [i.”